Cell Search

Executive Summary

Cell Search is a US-based diagnostics company that has commercialized the CELLSEARCH® Circulating Tumor Cell (CTC) Test, the only FDA-cleared blood test for enumerating CTCs in metastatic breast, prostate, and colorectal cancer. The test provides clinicians with a real-time, objective tool to monitor disease progression and guide treatment decisions, offering a non-invasive alternative to repeat biopsies. With a strong clinical validation base and growing adoption in oncology, Cell Search is positioned to expand its indications and leverage its liquid biopsy platform for broader cancer management. The company continues to invest in clinical studies to demonstrate the utility of CTC enumeration in additional cancer types and early-stage settings. Despite competition from emerging liquid biopsy players, Cell Search's first-mover advantage and established reimbursement support its niche in the oncology diagnostics market.

Upcoming Catalysts (preview)

• Q3 2026FDA clearance for additional cancer indication (e.g., pancreatic, lung)40% success
• Q2 2026Publication of landmark clinical study demonstrating CTC-guided therapy improves outcomes55% success
• Q4 2026Strategic partnership with a major pharmaceutical company for companion diagnostic development50% success